DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • November 21st, 2003 • Xcyte Therapies Inc • Pharmaceutical preparations
This Development and Supply Agreement (the “Agreement”) is made and entered into as of the 1st day of August, 1999 (the “Effective Date”) by and between XCYTE THERAPIES, INC., a Delaware corporation with offices at 1124 Columbia Street. Suite 130 Seattle, Washington 98104 (hereinafter referred to as “Xcyte”), and DYNAL A.S., a Norwegian corporation, with offices at P.O. Box 158, Skøyen, N-0212 Oslo, Norway (hereinafter referred to as “Dynal”).
LICENSE AND SUPPLY AGREEMENTLicense and Supply Agreement • November 21st, 2003 • Xcyte Therapies Inc • Pharmaceutical preparations • Washington
This License and Supply Agreement (“Agreement”) is entered into as of October 15th, 1999 (the “Effective Date”) by and between Xcyte Therapies, Inc., a Delaware corporation having a principal place of business at 2203 Airport Way South, Suite 300, Seattle, Washington 98134, United States (“Xcyte”), and Diaclone S.A., a French corporation having a principal place of business at 1 Boulevard Fleming, B.P. 1985 F-25020 Besancon Cedex, France (“Diaclone”).
CONFIDENTIAL August 28, 2003 AGREEMENTMutual Nondisclosure Agreement • November 21st, 2003 • Xcyte Therapies Inc • Pharmaceutical preparations • Washington
This agreement (the “Agreement”) set forth the principal terms of the collaboration (“Collaboration”) between Xcyte Therapies, Inc. (“Xcyte”) and Taiwan Cell Therapy Company (“TCTC”). This Agreement, including any attachments hereto, constitutes the sole agreement of the parties and supersedes all oral negotiations and prior writings with respect to the subject matter hereof.
WAIVER OF PREEMPTIVE RIGHTS AND AMENDMENT OF AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • November 21st, 2003 • Xcyte Therapies Inc • Pharmaceutical preparations
The undersigned, a party to that certain Amended and Restated Investor Rights Agreement dated February 5, 2002, as amended (the “Rights Agreement”) by and among Xcyte Therapies, Inc., a Delaware corporation (the “Company”) and the parties identified on Schedule A and Schedule B attached thereto (the “Investors”), by execution of this document, hereby (on behalf of itself and the other parties to the Rights Agreement): (a) amends the Rights Agreement, and (b) waives its preemptive rights, in each case pursuant to Section 8.1 of the Rights Agreement and as set forth below. Capitalized terms used herein but not defined herein shall have the meaning given to them in the Rights Agreement.
AMENDMENT NO. 2 TO LETTER OF INTENTXcyte Therapies Inc • November 21st, 2003 • Pharmaceutical preparations
This Amendment No. 2 to the Letter of Intent (the “Amendment”) is effective as of November 14, 2003 by and between Xcyte Therapies, Inc., a Delaware (U.S.A.) corporation (“Xcyte”), and Taiwan Cell Therapy Company, a corporation formed under the laws of Taiwan, R.O.C. (“TCTC”).
XCYTE THERAPIES, INC. CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT October 9, 2003Convertible Note and Warrant • November 21st, 2003 • Xcyte Therapies Inc • Pharmaceutical preparations • Washington
This Convertible Note and Warrant Purchase Agreement (the “Agreement”) is made as of the 9th day of October, 2003, by and between Xcyte Therapies, Inc., a Delaware corporation (the “Company”) and each of the purchasers listed on Exhibit A attached to this Agreement (each a “Purchaser” and together the “Purchasers”).
AMENDMENT NO. 1 TO LETTER OF INTENTXcyte Therapies Inc • November 21st, 2003 • Pharmaceutical preparations
This Amendment No. 1 to the Letter of Intent (the “Amendment”) is effective as of October 6, 2003 by and between Xcyte Therapies, Inc., a Delaware (U.S.A.) corporation (“Xcyte”), and Taiwan Cell Therapy Company, a corporation formed under the laws of Taiwan, R.O.C. (“TCTC”).
